To evaluate the efficacy of intravitreal bevacizumab injection (IVB) in acute central serous chorioretinopathy.

Retrospective chart review of 87 eyes of 80 patients. They received intravitreal bevacizumab injection (n = 40) and observed without any treatment or any medication (n = 47) for initial treatment of acute CSC. Patient demographics and best-corrected visual acuity (BCVA), central macular thickness (CMT) at baseline were analyzed. Then we had regular follow-ups of BCVA and CMT.

All patients showed improvement in visual acuity and resolution of subretinal fluid following treatment. In the bevacizumab-treated group, the mean BCVA improved from 0.22 ± to 0.11, mean CMT fell from 361.33 to 185.33 (µm) and recurrence rate was 47%. The conservative-treated group showed an improvement in BCVA from 0.23 at baseline to 0.14, mean CMT fell from 349.65 to 193.41 (µm) and recurrence rate was 70% ( p = 0.130, p = 0.908 and p = 0.030, respectively). However, the change of BCVA and CMT of 2 groups showed no differences at any follow-up visit. Recurrence rate was significantly low in bevacizumab-treated group.

The bevacizumab-treated group had relatively low rates of recurrence in acute CSC patients compared to the observation group. However, intravitreal bevacizumab showed no positive effect in BCVA and CMT of acute CSC patients compared to the observation group. Further investigation will be helpful to understand this therapy in patients with CSC.